**Recognizing and Treating Alzheimer’s Disease**

**Moving Towards Early Diagnosis and Disease Management**

***Additional Reading***

1. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. *Alzheimers Dement.* 2011;7:270-279.
2. Alzheimer’s Association. Alzheimer’s Association Report: 2015 Alzheimer’s disease facts and figures. *Alzheimer’s Dement*. 2015;11:332-384. Full report available at: https://www.alz.org/facts/downloads/facts\_figures\_2015.pdf.
3. Alzheimer's Disease International. World Alzheimer Report 2011: the benefits of early diagnosis and intervention. Available at www.alz.co.uk/research/WorldAlzheimerReport2011ExecutiveSummary.pdf
4. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. *J Neuropathol Exp Neurol*. 2012;71:266-273.
5. Bradford A, Kunik ME, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. *Alzheimer Dis Assoc Disord*. 2009;23:306-314.
6. Cordell CB, Borson S, Boustani M, et al. Alzheimer’s Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. *Alzheimers Dement*. 2013;9:141-150.
7. Cummings JL, Isaacson RS, Schmitt FA, Velting DM. A practical algorithm for managing Alzheimer’s disease: what, when, and why? *Ann Clin Transl Neurol.* 2015;2:307-323.
8. Cummings J, Cho W, Ward M, et al. A randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer's disease. Alzheimers Dement. 2014;10(4 Suppl):P275 (Abstract O4-11-06).
9. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. *N Engl J Med.* 2014;370:311-321.
10. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging—Alzheimer’s Association guidelines for the neuropathic assessment of Alzheimer’s disease. *Alzheimers Dement.* 2012;8:1-13.
11. Jack CR Jr., Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol.* 2013;12:207-216.
12. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. *Alzheimer’s Dement.* 2013;9:e1-e16.
13. Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer’s disease. *Cold Spring Harb Perspect Med*. 2012;2:a006213.
14. Lin JS, O'Connor E, Rossom RC, et al. Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force Rockville, MD: Agency for Healthcare Research and Quality; 2013. Available at [www.ncbi.nlm.nih.gov/pubmedhealth/PMH0063382/pdf/PubMedHealth\_PMH0063382.pdf](http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0063382/pdf/PubMedHealth_PMH0063382.pdf)
15. Liu-Seifert H, Siemers E, Holdridge KC, et al. Delayed-start analysis: mild Alzheimer's disease patients in solanezumab trials, 3.5 years. *Alzheimers Dement Transl Res Clin Interventions.* 2015;1:111-121. <http://dx.doi.org/10.1016/j.trci.2015.06.006>
16. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. *Alzheimers Dement.* 2011;7:263-269.
17. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. *N Engl J Med.* 2014;370:322-333.
18. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7(3):280–92.
19. Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease. Alzheimer's Res Ther. 2014; 6:89.

**Websites**

Alzheimer’s Association, http://www.alz.org/

Alzheimer’s Foundation of America, http://www.alzfdn.org/

Family Caregiver Alliance, http://www.caregiver.org/

Alzheimer’s Disease Education and Referral Center, National Institute on Aging, https://www.nia.nih.gov/alzheimers

Alzheimer’s Disease International, http://www.alz.co.uk/

For more information, please visit [www.detectalz.com](http://www.detectalz.com)